According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months as Xience in angioplasty guided by intravascular imaging. This research was presented at the virtual EuroPCR 2021 Congress. Previous studies (BIOSTEMI and BIOFLOW V) showed that Orsiro was superior to Xience in reducing target-lesion revascularization. However, the reason behind this…